Canaccord raised the firm’s price target on Atai Life Sciences (ATAI) to $14 from $11 and keeps a Buy rating on the shares. The firm noted their merger with privatley held Beckley is on track to close in Q4 while recently announcing the FDA granted breakthrough therapy designation (BTD) to Beckley’s BPL-003 (intranasal mebufotenin), which had solid Phase 2 data for treatment-resistant depression.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATAI:
- ATAI Life Sciences Closes $149.5 Million Public Offering
- 3 Best Stocks to Buy Now, 10/20/2025, According to Top Analysts
- Atai Life Sciences announces FDA breakthrough designation for BPL-003
- Atai Life Sciences price target raised to $10 from $7 at Jefferies
- Atai Life Sciences 23.725M share Spot Secondary priced at $5.48